Eisai invests £48M in UK manufacturing with government backing

Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) announced a strategic investment of approximately £48 million at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF).

The investment is intended to establish supply chain and packaging capabilities for medicines requiring cold-chain management, including lecanemab, an Alzheimer's treatment. The project will expand the Hatfield site's role beyond traditional oral solid dose operations to include packaging and supply of temperature-controlled medicines for injection and infusion.

LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing in the UK and improve supply resilience. The investment is subject to terms and conditions.

Planned infrastructure includes ambient and cold-chain warehouses, packaging buildings, packaging lines, and expanded goods receipt and dispatch functions. The project will be carried out in multiple phases. Eisai also plans to transition from external contract manufacturers to an in-house packaging model.

Science Minister Lord Vallance said the investment "will secure the supply of vital medicines, including treatments for Alzheimer's disease," and noted it "will also support the creation of new skilled jobs in Hatfield."

The Hatfield site is expected to serve regions including Europe, the Middle East, and Africa. According to the company's statement, enhanced capabilities will include multi-language and small-batch packaging and advanced quality management.

You May Also Be Interested In

• Bloom Energy rejects short-seller report on finances and supply chain
• All In FutureTech plans to integrate LittleVault into its platform
• Oracle joins IMSA Labs as founding partner with new startup program